PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY TO ASSESS THE BURDEN OF HERPES ZOSTER DISEASE IN THE EYE: BASELINE RESULTS OF INITIAL PATIENTS

BACKGROUND
With about 1 million cases of herpes zoster in the US annually, approximately 10-20% are complicated by herpes zoster ophthalmicus (HZO),1 many of which have ocular involvement that can lead to vision threatening complications.2

Objectives: describe the frequency, duration, and impact of HZO complications; and vision-specific health-related quality of life and depressive symptoms in acute HZO patients.

RESULTS
Patients’ ocular diagnoses and self-reported pain and symptoms

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain above</td>
<td>n=9</td>
</tr>
<tr>
<td>Pain to the left or right</td>
<td>n=9</td>
</tr>
<tr>
<td>Pain below</td>
<td>n=9</td>
</tr>
<tr>
<td>Sensitivity to light</td>
<td>n=9</td>
</tr>
<tr>
<td>Redness in the eye</td>
<td>n=9</td>
</tr>
<tr>
<td>Eyelid droopyness compared to healthy eye</td>
<td>n=9</td>
</tr>
<tr>
<td>Feeling of sand or grit in the eye</td>
<td>n=9</td>
</tr>
<tr>
<td>Tearing</td>
<td>n=6</td>
</tr>
<tr>
<td>Dizziness in the eye</td>
<td>n=4</td>
</tr>
<tr>
<td>Pain behind</td>
<td>n=8</td>
</tr>
<tr>
<td>Pain</td>
<td>n=6</td>
</tr>
</tbody>
</table>

CONCLUSIONS
This study represents initial patients’ data from the first large-scale effort to quantify HZO burden.
These preliminary data show that HZO commonly has an impact on the eye, including pain and other self-reported outcomes.
Ultimately, the findings may be used to help develop a formal patient-reported symptom scale for use in research and clinical practice.

METHODS
This ongoing, 1-year, prospective, multicenter (6 major US ophthalmology practices), observational cohort study aims to recruit 300 patients; herein, we report diagnoses and baseline patient-reported outcomes for the first 13 patients.

Patient selection & study design
Inclusion criteria:
• ≥18 years old
• Clinically active HZO
• English or Spanish speaking
• Not enrolled in a concurrent study

Clinical form: Assessment of demographics and HZO characteristics

Baseline
n=13

Further HZO characteristics assessment

Demographic characteristics

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>11/13 Women</td>
</tr>
<tr>
<td>Age</td>
<td>71 years</td>
</tr>
</tbody>
</table>

Other ocular diagnostic: HZO, herpes zoster ophthalmicus disease; other ocular problems: n=9. HZ, herpes zoster.
 Patients may have more than one ocular symptom/diagnosis, from the total have n=13. Symptoms are not mutually exclusive or specific to one eye.

Vision-Related Quality of Life (NEI-VFQ-25)

Overall score
Driving
General health
Ocular pain
Vision-specific mental health
Vision-specific role difficulties
General vision
Near activities

Pain (ZBPI)

Worst pain severity
Average pain severity
Overall pain severity

Depressive Symptoms (PHQ-8)

Best
Worst

Funding: GlaxoSmithKline Biologicals SA (GSK study identifiers: 209235/HO-17-17967)